Risk factors

CG Oncology (CGON) risk factors

Item 1A of every CG Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open CGON in Gloom →
CG Oncology's chart, financials and news, free in your browser.Open CGON in Gloom →
  • FY2025 10-K risk factors
    77 risks4 new5 dropped5 reworded

    Clinical execution and first-time BLA submission are newly emphasized as CG Oncology advances cretostimogene through multiple Phase 3 trials.

    Filed Feb 27, 2026
  • FY2024 10-K risk factors
    78 risks

    Clinical-stage biopharmaceutical company dependent entirely on the success of its lead product candidate, cretostimogene, for cancer treatment.

    Filed Mar 28, 2025